PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX

   PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering
                  Long-Acting Coagulation Factors VII and IX

PR Newswire

NES-ZIONA, Israel, April 8, 2013

NES-ZIONA, Israel, April 8, 2013 /PRNewswire/ --PROLOR Biotech, Inc. (NYSE
MKT: PBTH) today announced that it received a notice of allowance from the
U.S. Patent and Trademark Office for a new patent application covering the
company's proprietary long-acting CTP-enhanced coagulation factors for the
treatment of hemophilia: Factor VIIa-CTP, Factor Vll-CTP and Factor IX-CTP.
The allowed claims cover both product composition and treatment methods.

"This new patent allowance is important for PROLOR, as we move forward with
plans to initiate a Phase II clinical study of our long-acting Factor VIIa-CTP
in early 2014," said Shai Novik, President of PROLOR. "Our intellectual
property strategy is designed to provide multiple layers of protection for our
product portfolio, and we believe that this new patent will provide additional
reinforcement to our existing patent estate for our hemophilia drug

PROLOR previously presented preclinical data on its long-acting versions of
factor Vlla and factor IX. In hemophilic mice, Factor VIIa-CTP demonstrated
superior performance on multiple parameters and resulted in greater survival
of the subjects compared to commercially available factor VIIa. Factor
VIIa-CTP also demonstrated the potential for subcutaneous administration in
addition to administration using standard IV dosing.Factor IX-CTP
demonstrated significantly longer duration of clotting activity in hemophilic
mice, and bleeding episodes were significantly shorter and less intense
compared with commercially available factor IX. None of the animals treated
with Factor IX-CTP had any spontaneous re-occurring bleeding events, as
compared with a 50% incidence of re-bleeding events for the group treated with
commercially available factor IX.

The new patent is expected to issue in the next few months.

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology, primarily to develop
longer-acting proprietary versions of already approved therapeutic proteins
that currently generate billions of dollars in annual global sales. The CTP
technology is applicable to virtually all proteins. PROLOR is currently
developing a long-acting version of human growth hormone, which successfully
completed a Phase II clinical trial. It also is developing long-acting
versions of factor VIIa and factor IX for hemophilia and a GLP-1/Glucagon dual
receptor agonist peptide for diabetes and obesity, all of which are in
preclinical development. For more information, visit

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

Shai Novik, President            Barbara Lindheim

PROLOR Biotech, Inc.    BLL Partners, LLC

Tel: +1 866 644-7811                 +1 212 584-2276



Press spacebar to pause and continue. Press esc to stop.